MedApp (WAR:MDA) Cyclically Adjusted Revenue per Share: zł0.04 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:MDA MedApp SA WAR:MDA
39 GF Score
Price zł0.20
GF Value zł0.24
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is MedApp Cyclically Adjusted Revenue per Share?

MedApp WAR:MDA +4.45% 39 Cyclically Adjusted Revenue per Share is zł0.04 as of Mar. 2026. GuruFocus rates WAR:MDA with a GF Score™ of 39/100 and a GF Value™ of zł0.24 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

MedApp's adjusted revenue per share for the three months ended in Mar. 2026 was zł0.012. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is zł0.04 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -9.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-16), MedApp's current stock price is zł0.1995. MedApp's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was zł0.04. MedApp's Cyclically Adjusted PS Ratio of today is 4.99.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of MedApp was 29.70. The lowest was 2.08. And the median was 8.25.


MedApp  (WAR:MDA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

MedApp's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.1995/0.04
=4.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of MedApp was 29.70. The lowest was 2.08. And the median was 8.25.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


MedApp Cyclically Adjusted Revenue per Share Related Terms


MedApp Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for MedApp's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MedApp Cyclically Adjusted Revenue per Share Chart

MedApp Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 0.04 0.04 0.04 0.03

MedApp Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.04 0.03 0.04

WAR:MDA vs VEEV, BTSG, TEM: Cyclically Adjusted Revenue per Share Comparison

For the Health Information Services subindustry, MedApp's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedApp Cyclically Adjusted PS Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, MedApp's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where MedApp's Cyclically Adjusted PS Ratio falls into.


WAR:MDA
39GF Score
MedApp SA WAR:MDA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MedApp Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, MedApp's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.012/163.0700*163.0700
=0.012

Current CPI (Mar. 2026) = 163.0700.

MedApp Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 99.552 0.000
201609 0.000 99.064 0.000
201612 0.000 100.366 0.000
201703 0.000 101.018 0.000
201706 0.000 101.180 0.000
201709 0.000 101.343 0.000
201712 0.001 102.564 0.002
201803 0.000 102.564 0.000
201806 0.000 103.378 0.000
201809 0.001 103.378 0.002
201812 0.000 103.785 0.000
201903 0.000 104.274 0.000
201906 0.000 105.983 0.000
201909 0.001 105.983 0.002
201912 0.013 107.123 0.020
202003 0.000 109.076 0.000
202006 0.001 109.402 0.001
202009 0.004 109.320 0.006
202012 0.019 109.565 0.028
202103 0.008 112.658 0.012
202106 0.014 113.960 0.020
202109 0.015 115.588 0.021
202112 0.014 119.088 0.019
202203 0.012 125.031 0.016
202206 0.006 131.705 0.007
202209 0.005 135.531 0.006
202212 0.004 139.113 0.005
202303 0.007 145.950 0.008
202306 0.007 147.009 0.008
202309 0.002 146.113 0.002
202312 0.006 147.741 0.007
202403 0.004 149.044 0.004
202406 0.009 150.997 0.010
202409 0.010 153.439 0.011
202412 0.007 154.660 0.007
202503 0.005 157.021 0.005
202506 0.003 157.509 0.003
202509 0.004 158.000 0.004
202512 0.003 158.320 0.003
202603 0.012 163.070 0.012

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of zł0.04 mean?
MedApp (WAR:MDA) has a Cyclically Adjusted Revenue per Share of zł0.04 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on MedApp and its competitors.
Is MedApp's Cyclically Adjusted Revenue per Share too high?
MedApp's current Cyclically Adjusted Revenue per Share is zł0.04. Overall, MedApp has a GF Score™ of 39/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MedApp's Cyclically Adjusted Revenue per Share compare to VEEV and BTSG?
MedApp's Cyclically Adjusted Revenue per Share of zł0.04 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Healthcare Providers & Services company?
A good Cyclically Adjusted Revenue per Share depends on the Healthcare Providers & Services industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on MedApp and its competitors. MedApp's current Cyclically Adjusted Revenue per Share is zł0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedApp stock overvalued right now?
Based on GuruFocus' analysis, MedApp (WAR:MDA) is currently considered Modestly Undervalued. The stock's GF Value™ is zł0.24, compared to a current price of zł0.20 — trading 16.9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is zł0.04. MedApp's overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For MedApp (WAR:MDA), the current Cyclically Adjusted Revenue per Share is zł0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MedApp (WAR:MDA) Overvalued in 2026?

Based on GuruFocus' analysis, MedApp stock appears to be undervalued. The current stock price of zł0.20 is trading 16.9% below its estimated GF Value™ of zł0.24. GuruFocus considers MedApp to be Modestly Undervalued.

Key valuation signals for WAR:MDA:

  • Cyclically Adjusted Revenue per Share: zł0.04
  • GF Value™: zł0.24 vs. price of zł0.20 (16.9% below fair value)
  • GF Score™: 39/100 with 5 warning signs

No single metric tells the full story. See the WAR:MDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


MedApp Business Description

Address Dobre Pasterza 122A, Krakow, POL, 31-416
MedApp SA develops mobile solutions for medicine. The company's products include Carna Life and Holo.
39GF Score

Get the complete analysis for WAR:MDA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł0.20
Price
zł0.24
GF Value